PfSPZ-LARC2 Vaccine

BIOLOGICAL2 trials

Sponsors

Sanaria Inc.

Conditions

Malaria FalciparumMalaria Infection

Phase 1

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Active, not recruitingNCT06652737

Sanaria Inc.Malaria Falciparum, Malaria Infection

Start: 2025-03-04End: 2026-03-01Target: 75Updated: 2026-03-20

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Not yet recruitingNCT06862453

Sanaria Inc.Malaria Falciparum

Start: 2026-03-01End: 2026-12-30Target: 58Updated: 2026-03-23